Notwithstanding positive clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant opposition from managed care entities. The insurers are often creating obstacles to coverage, like steep cost criteria and prior authoriza